ADCT ADC Therapeutics SA - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ADCT Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Biotechnology
Current Price
Live
$3.61
Analyst Target
$8.0
+121.6%
Upside
52W High
$4.8
52W Low
$1.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$447.2M
P/E
N/A
ROE
N/A
Profit margin
-222.0%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 1/9, indicating significant fundamental deterioration. Despite negative profitability metrics across the board—including a -221.97% profit margin and negative price-to-book ratio—the stock shows signs of recent momentum, with a 1-year price return of +105.1% and a strong_buy analyst consensus. Cash position appears healthy with a current ratio of 4.63, though enterprise value and debt metrics are unavailable, limiting full risk assessment. The absence of Altman Z-Score and Graham Number prevents definitive value judgment, but elevated valuation multiples and negative earnings suggest speculative risk.
Key Strengths
Strong analyst recommendation with consensus of strong_buy from 5 analysts
High liquidity position indicated by current ratio of 4.63 and quick ratio of 4.15
Recent positive earnings surprises: 2 out of last 4 quarters beat estimates with average surprise of 7.76%
Significant year-over-year EPS growth improvement at +28.6% and Q/Q EPS growth of +40.0%
Recent price momentum: +105.1% over 1 year despite long-term underperformance
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and weak operating performance
Persistent unprofitability with negative gross, operating, and net margins across all recent periods
Revenue declining YoY by -11.00%, indicating weakening top-line fundamentals
Negative Price/Book of -1.71 and Forward P/E of -2.42 imply no earnings power and eroding book value
Lack of key financial data (EV, debt, cash, ROIC) creates information asymmetry and limits risk evaluation
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
25
60
38
20
0
AI Verdict
Speculative opportunity with high risk due to fundamental weaknesses offset by recent momentum and analyst optimism
Key drivers: Analyst strong_buy consensus, Recent EPS growth acceleration, High short-term price momentum, Weak Piotroski F-Score, Negative profitability metrics
Confidence
70%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Low current price at $3.61 may attract speculative interest
Watchpoints
- Forward P/E of -2.42 indicates no earnings
- Price/Book of -1.71 shows book value erosion
- Price/Sales of 5.95 is high for a shrinking revenue company
- No Graham Number or Intrinsic Value available
Future
60/100
Ref Growth rates
Positives
- Year-over-year EPS growth of +28.6%
- Q/Q EPS growth of +40.0%
- Revenue decline appears to be stabilizing
Watchpoints
- Revenue growth is negative at -11.00% YoY
- No visibility on future profitability inflection
Past
38/100
Ref Historical trends
Positives
- Some history of beating earnings estimates (12 of 24 quarters)
Watchpoints
- Frequent large earnings misses, including -105.2% and -100.0% surprises
- Long-term price performance poor: -89.4% over 5 years
- Consistently negative margins over multiple years
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 4.63 suggests short-term liquidity is strong
- Quick ratio of 4.15 indicates ability to meet near-term obligations
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- No Altman Z-Score available to assess bankruptcy risk
- ROA of -23.98% reflects poor asset efficiency
- Debt/Equity and total debt/cash figures unavailable
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.61
Analyst Target
$8.0
Upside/Downside
+121.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADCT and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
Primary
|
-89.4% | -22.9% | +105.1% | +10.1% | +2.3% | -0.3% |
|
ASMB
Assembly Biosciences, Inc.
Peer
|
-61.4% | +51.6% | +88.4% | +51.0% | -17.6% | -4.6% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.9% | -19.8% | -4.9% | +24.1% | -3.3% | +1.9% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
BCYC
Bicycle Therapeutics plc
Peer
|
-74.2% | -74.7% | -47.5% | -20.1% | -0.6% | +6.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.42
PEG Ratio
N/A
P/B Ratio
-1.71
P/S Ratio
5.95
EV/Revenue
8.91
EV/EBITDA
-5.51
Market Cap
$447.2M
Profitability
Profit margins and return metrics
Profit Margin
-221.97%
Operating Margin
-186.23%
Gross Margin
-57.42%
ROE
N/A
ROA
-23.98%
Growth
Revenue and earnings growth rates
Revenue Growth
-11.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
4.63
Strong
Quick Ratio
4.15
Excellent
Cash/Share
$1.9
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-02
$N/A
2025-11-10
$-0.3
+17.4% surprise
2025-08-12
$-0.5
-4.9% surprise
2025-05-14
$-0.36
+10.7% surprise
Healthcare Sector Comparison
Comparing ADCT against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Profit Margin
-221.97%
This Stock
vs
-20.8%
Sector Avg
+967.3%
(Superior)
Revenue Growth
-11.0%
This Stock
vs
62.23%
Sector Avg
-117.7%
(Slower)
Current Ratio
4.63
This Stock
vs
3.45
Sector Avg
+34.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $447.2M | - | -% | -222.0% | $3.61 | |
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $443.04M | - | -36.9% | -103.6% | $28.01 | |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $435.26M | - | -15.3% | -9.0% | $10.56 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | |
|
BCYC
Bicycle Therapeutics plc
|
BEARISH | $482.11M | - | -34.6% | -% | $6.95 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
HC Wainwright & Co.
2025-10-16
Buy
Buy
Guggenheim
2025-08-13
Buy
Buy
Past News Coverage
Recent headlines mentioning ADCT from our newsroom.
Newest → oldest
No matching news yet.